APRE

Aprea Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website aprea.com
Employees(FY) 9
ISIN US03836J2015

Performance

-13.34%

+0.99%

+4.45%

-25.06%

-35.11%

YTD

-22.19%

Profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of APRE 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score at 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of APRE

Stock Rank

Recent News & Updates

2024-12-10 19:30
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward(Globenewswire)
2024-11-12 20:55
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher(Yahoo Finance)
2024-11-06 20:20
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates(Yahoo Finance)
2024-11-06 19:00
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-10-23 20:40
Aprea Therapeutics presents preliminary results on APR-1051(Yahoo Finance)
2024-10-22 20:30
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics(Globenewswire)
2024-10-13 20:30
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit(Globenewswire)
2024-10-10 07:03
Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc(Yahoo Finance)
2024-10-09 20:30
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics(Globenewswire)
2024-10-08 20:30
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development(Globenewswire)
2024-09-24 20:00
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024(Globenewswire)
2024-09-19 20:35
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing(Yahoo Finance)
2024-09-16 00:07
Life Sciences Virtual Investor Forum Agenda Announced for September 19th(Yahoo Finance)
2024-09-11 20:30
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19(Globenewswire)
2024-09-09 05:15
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference(Globenewswire)
2024-09-09 04:05
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference(Globenewswire)
2024-08-27 20:30
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference(Globenewswire)
2024-08-11 21:45
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-11 20:30
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-07-16 20:00
Alltrna Announces Updates to Its Board of Directors(Prnewswire)
2024-06-20 20:00
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024(Globenewswire)
2024-06-16 20:30
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051(Globenewswire)
2024-05-27 20:45
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial(Globenewswire)
2024-05-14 01:53
APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-13 20:30
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-05-13 04:01
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference(Globenewswire)
2024-05-01 21:15
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)(Globenewswire)
2024-04-10 00:00
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024(Globenewswire)
2024-03-26 01:53
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023(Investorplace)
2024-03-25 19:45
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.